PMID: 11728296Dec 1, 2001

Perindopril

Heart Disease
D C O'LoughlinD Singh

Abstract

Perindopril is the newest angiotensin-converting enzyme inhibitor to be approved in the United States. It is indicated for the treatment of essential hypertension either alone or in combination with other antihypertensives, especially thiazide diuretics. Perindopril must be converted to perindoprilat, its active metabolite. The drug's prolonged duration of action allows for once daily administration. This article reviews clinical trials performed using perindopril alone and in combination to treat essential hypertension. The use of perindopril for congestive heart failure is reviewed. The influence of perindopril on arterial wall properties is discussed. Tolerability, drug interactions, and dosage and administration of the drug are reviewed.

Related Concepts

Angiotensin-Converting Enzyme Inhibitors
Benzothiadiazines
Diastolic Blood Pressure
Diuretic Effect
Polychemotherapy
Myocardial Failure
Hypertensive Disease
New Drug Approval Process
Perstarium
Sodium Chloride Symporter Inhibitors

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.